🟢 Nasus Pharma is trading 8.6% up today after first patient dosed in NS003 Phase 1

Nasus Pharma is trading 8.6% higher at $4.01 after the first patient was enrolled and dosed in its NS003 Phase 1 study.

• The September 29 announcement concerned NS003, the company’s intranasal ondansetron formulation.
• Nasus Pharma expects topline pharmacokinetic data in Q4 2026.
• Shares have continued rising from the September 30 close of $3.69; the healthcare sector is down while major indices are modestly higher.